Tags

Type your tag names separated by a space and hit enter

Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
J Clin Oncol. 2007 Oct 20; 25(30):4772-8.JC

Abstract

PURPOSE

Response to endocrine therapy in breast cancer correlates with estrogen receptor (ER) and progesterone receptor (PgR) status. It is usually easier to decide treatment strategies in cases of double-positive/-negative phenotypes than in single-positive tumors.

PATIENTS AND METHODS

We have examined a large and well-characterized series of primary invasive breast carcinoma (1,944 cases) with long-term clinical follow-up and hormone therapy data. Patients were stratified according to ER and PgR expression and the study was focused on the single-positive groups (ER-/PgR+ and ER+/PgR-), to assess their main features and evaluate any prognostic and predictive difference between them and compare them with the double-positive/-negative tumors.

RESULTS

ER+/PgR-tumors were found more frequently in elderly, postmenopausal women. The majority were grade 2 ductal/no specific type carcinomas. There was no difference between the two groups with regard to lymph node stage. Survival analyses showed no difference between the two groups in terms of disease-free interval and overall survival. However, when compared with the double-negative phenotype, ER+/PgR-showed an association with better outcome but no such survival advantage was detected in case of ER-/PgR+ tumors. In the group of patients with ER+ tumors who received adjuvant hormonal therapy, absence of PgR (ER+/PgR-) was an independent predictor of development of recurrence and shorter survival and, hence, poorer response to hormonal therapy.

CONCLUSION

ER+/PgR-and ER-/PgR+ tumors are biologically and clinically distinct groups of breast cancer that may require different treatment strategies with ER-/PgR+ exhibiting more aggressive behavioral characteristics.

Authors+Show Affiliations

Department of Histopathology and Surgery, School of Molecular Medical Sciences, Nottingham University Hospitals National Health Service Trust and University of Nottingham, Nottingham, United Kingdom. emadrakha@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

17876012

Citation

Rakha, Emad A., et al. "Biologic and Clinical Characteristics of Breast Cancer With Single Hormone Receptor Positive Phenotype." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 25, no. 30, 2007, pp. 4772-8.
Rakha EA, El-Sayed ME, Green AR, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007;25(30):4772-8.
Rakha, E. A., El-Sayed, M. E., Green, A. R., Paish, E. C., Powe, D. G., Gee, J., Nicholson, R. I., Lee, A. H., Robertson, J. F., & Ellis, I. O. (2007). Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 25(30), 4772-8.
Rakha EA, et al. Biologic and Clinical Characteristics of Breast Cancer With Single Hormone Receptor Positive Phenotype. J Clin Oncol. 2007 Oct 20;25(30):4772-8. PubMed PMID: 17876012.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. AU - Rakha,Emad A, AU - El-Sayed,Maysa E, AU - Green,Andrew R, AU - Paish,E Claire, AU - Powe,Desmond G, AU - Gee,Julia, AU - Nicholson,Robert I, AU - Lee,Andrew H S, AU - Robertson,John F R, AU - Ellis,Ian O, Y1 - 2007/09/17/ PY - 2007/9/19/pubmed PY - 2007/11/14/medline PY - 2007/9/19/entrez SP - 4772 EP - 8 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J Clin Oncol VL - 25 IS - 30 N2 - PURPOSE: Response to endocrine therapy in breast cancer correlates with estrogen receptor (ER) and progesterone receptor (PgR) status. It is usually easier to decide treatment strategies in cases of double-positive/-negative phenotypes than in single-positive tumors. PATIENTS AND METHODS: We have examined a large and well-characterized series of primary invasive breast carcinoma (1,944 cases) with long-term clinical follow-up and hormone therapy data. Patients were stratified according to ER and PgR expression and the study was focused on the single-positive groups (ER-/PgR+ and ER+/PgR-), to assess their main features and evaluate any prognostic and predictive difference between them and compare them with the double-positive/-negative tumors. RESULTS: ER+/PgR-tumors were found more frequently in elderly, postmenopausal women. The majority were grade 2 ductal/no specific type carcinomas. There was no difference between the two groups with regard to lymph node stage. Survival analyses showed no difference between the two groups in terms of disease-free interval and overall survival. However, when compared with the double-negative phenotype, ER+/PgR-showed an association with better outcome but no such survival advantage was detected in case of ER-/PgR+ tumors. In the group of patients with ER+ tumors who received adjuvant hormonal therapy, absence of PgR (ER+/PgR-) was an independent predictor of development of recurrence and shorter survival and, hence, poorer response to hormonal therapy. CONCLUSION: ER+/PgR-and ER-/PgR+ tumors are biologically and clinically distinct groups of breast cancer that may require different treatment strategies with ER-/PgR+ exhibiting more aggressive behavioral characteristics. SN - 1527-7755 UR - https://www.unboundmedicine.com/medline/citation/17876012/Biologic_and_clinical_characteristics_of_breast_cancer_with_single_hormone_receptor_positive_phenotype_ L2 - https://ascopubs.org/doi/10.1200/JCO.2007.12.2747?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -